聚乙二醇化脂质体多柔比星不良反应管理 中国专家共识(2020版).

As a new type of anthracyclines, pegylated liposomal doxorubicin ( PLD) is widely used in the treatment of a variety of malignant tumors, including soft tissue sarcoma, ovarian cancer,breast cancer, multiple mycloma, and so on. Compared with traditional anthracydines, PLD can significantly decrease the incidences of adverse events such as cardiac toxicity and alopecia. However, the use of PLD will he accompanied with toxic side effects such as hand-foot syndrome, oral mucositis, and infusion reaction. This consensus will mainly focus on the mechanism, prevention and treatment of adverse events of PLD, in order In improve the therapeutic efficency of PLD and lifequality of patients. [ABSTRACT FROM AUTHOR]